Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis : Methodology and correlation with cardiac functional parameters
© 2021. The Author(s)..
BACKGROUND: Volumetric evaluation of 99mTechnetium-pyrophosphate (99mTc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). We investigated the methodology and assessed its relationship with conventional parameters.
METHODS AND RESULTS: We retrospectively evaluated 99mTc-PYP SPECT/CT scans of 25 patients who underwent endomyocardial biopsy and/or gene testing. Fourteen (56%) patients were diagnosed with ATTR-CA. SPECT/CT images were acquired at 3 hours after injection. Total volumes of the myocardial regions where uptakes were > 1.2 and 1.4 × aortic blood pool SUVmax were evaluated and defined as cardiac pyrophosphate volume (CPV1.2 and CPV1.4). The heart-to-contralateral lung (H/CL) ratio and myocardial SUVmax were also calculated. CPV1.2 achieved the highest sensitivity and specificity in diagnosing ATTR-CA. In patients diagnosed with ATTR-CA (n = 14), CPV1.2 negatively correlated with left ventricular ejection fraction and positively correlated with left ventricular posterior wall thickness and QRS duration. The correlation was stronger in CPV1.2 than in the H/CL ratio and SUVmax.
CONCLUSION: Volumetric evaluation of 99mTc-PYP SPECT/CT may be superior to the H/CL ratio and SUVmax in assessing the disease burden of ATTR-CA. Larger studies are warranted to clarify whether volumetric measurement can assess prognosis and disease progression.
| Errataetall: |
CommentIn: J Nucl Cardiol. 2022 Dec;29(6):3111-3114. - PMID 34921352 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology - 29(2022), 6 vom: 25. Dez., Seite 3102-3110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Watanabe, Satoru [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.01.2023 Date Revised 30.01.2024 published: Print-Electronic CommentIn: J Nucl Cardiol. 2022 Dec;29(6):3111-3114. - PMID 34921352 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12350-021-02857-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334438993 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334438993 | ||
| 003 | DE-627 | ||
| 005 | 20240130231941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12350-021-02857-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM334438993 | ||
| 035 | |a (NLM)34907500 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Watanabe, Satoru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis |b Methodology and correlation with cardiac functional parameters |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2023 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Nucl Cardiol. 2022 Dec;29(6):3111-3114. - PMID 34921352 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Volumetric evaluation of 99mTechnetium-pyrophosphate (99mTc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). We investigated the methodology and assessed its relationship with conventional parameters | ||
| 520 | |a METHODS AND RESULTS: We retrospectively evaluated 99mTc-PYP SPECT/CT scans of 25 patients who underwent endomyocardial biopsy and/or gene testing. Fourteen (56%) patients were diagnosed with ATTR-CA. SPECT/CT images were acquired at 3 hours after injection. Total volumes of the myocardial regions where uptakes were > 1.2 and 1.4 × aortic blood pool SUVmax were evaluated and defined as cardiac pyrophosphate volume (CPV1.2 and CPV1.4). The heart-to-contralateral lung (H/CL) ratio and myocardial SUVmax were also calculated. CPV1.2 achieved the highest sensitivity and specificity in diagnosing ATTR-CA. In patients diagnosed with ATTR-CA (n = 14), CPV1.2 negatively correlated with left ventricular ejection fraction and positively correlated with left ventricular posterior wall thickness and QRS duration. The correlation was stronger in CPV1.2 than in the H/CL ratio and SUVmax | ||
| 520 | |a CONCLUSION: Volumetric evaluation of 99mTc-PYP SPECT/CT may be superior to the H/CL ratio and SUVmax in assessing the disease burden of ATTR-CA. Larger studies are warranted to clarify whether volumetric measurement can assess prognosis and disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Amyloid heart disease | |
| 650 | 4 | |a Cardiomyopathy | |
| 650 | 4 | |a Hybrid imaging | |
| 650 | 4 | |a Image analysis | |
| 650 | 4 | |a SPECT | |
| 650 | 7 | |a diphosphoric acid |2 NLM | |
| 650 | 7 | |a 4E862E7GRQ |2 NLM | |
| 650 | 7 | |a Diphosphates |2 NLM | |
| 650 | 7 | |a Technetium Tc 99m Pyrophosphate |2 NLM | |
| 650 | 7 | |a 5L76I61H2B |2 NLM | |
| 650 | 7 | |a Prealbumin |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 700 | 1 | |a Nakajima, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Wakabayashi, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoneyama, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Shohei |e verfasserin |4 aut | |
| 700 | 1 | |a Komatsu, Junji |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Inaki, Anri |e verfasserin |4 aut | |
| 700 | 1 | |a Kinuya, Seigo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology |d 1994 |g 29(2022), 6 vom: 25. Dez., Seite 3102-3110 |w (DE-627)NLM087703971 |x 1532-6551 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:6 |g day:25 |g month:12 |g pages:3102-3110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12350-021-02857-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 6 |b 25 |c 12 |h 3102-3110 | ||